Clover Health Investments Crop. ($CLOV) Stock Forecast: Up 5.4% Today

What is Clover Health Investments Crop.?

Clover Health (CLOV) operates in the healthcare technology sector, specializing in Medicare Advantage plans. The company's stock price has surged by 110% since the beginning of the year and recently obtained a 4.5-Star Medicare rating.

Why is Clover Health Investments Crop. going up?

CLOV stock is up 5.4% on Jun 18, 2026 14:56

• Today's rise in Clover Health's stock price reflects positive market sentiment fueled by its strong performance so far in 2021 and the recent upgrade in its Medicare star rating.
• The sale of shares by Clover Health's VP of Finance and Controller to address tax obligations resulting from vested restricted stock units raised initial concerns. However, since these transactions were mandatory rather than optional, they are perceived as part of routine financial management rather than an indication of negative internal sentiments.
• The overall surge in Clover Health's stock value today is likely a result of its robust financial performance, positive industry acknowledgment, and routine financial activities by company executives.
• The market appears to be responding positively to Clover Health's recent achievements and financial decisions, leading to an increase in the stock price amid an optimistic industry outlook.

CLOV Price Chart

CLOV Technical Analysis

CLOV News

Clover Health VP of finance Oldakowski sells $58,815 in stock By Investing.com

Joseph Frank Oldakowski, VP of Finance at Clover Health, sold 12,102 shares worth $58,815 to cover tax obligations from vested restricted stock units. This "sell to cover" transaction was not discretionary and occurred as Clover Health's stock is up 110% year-to-date, trading near its 52-week high. The company recently reported mixed Q1 2026 earnings, but achieved a significant upgrade to a 4.5-Star Medicare rating following a favorable court ruling.

https://m.au.investing.com/news/insider-trading-news/clover-health-vp-of-finance-oldakowski-sells-58815-in-stock-93CH-4492373?ampMode=1

Clover Health VP of finance Oldakowski sells $58,815 in stock

Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health Investments Corp., sold 12,102 shares totaling $58,815 to cover tax withholding obligations for restricted stock units. This "sell to cover" transaction was not a discretionary trade, and Oldakowski still holds 299,067 shares. The sale comes as Clover Health's stock shows significant year-to-date returns and the company recently reported mixed Q1 2026 earnings but received a major upgrade in its Medicare star rating.

https://m.uk.investing.com/news/insider-trading-news/clover-health-vp-of-finance-oldakowski-sells-58815-in-stock-93CH-4732927?ampMode=1

Clover Health (CLOV) finance VP sells 12,102 shares in tax-related RSU transaction

Joseph Frank Oldakowski, VP of Finance and Controller at Clover Health, sold 12,102 shares of Class A Common Stock for $4.86 per share to cover tax withholding obligations related to the vesting of restricted stock units. This "sell to cover" transaction was mandatory and not a discretionary trade. Following the sale, Oldakowski directly holds 299,067 shares.

https://www.stocktitan.net/sec-filings/CLOV/form-4-clover-health-investments-corp-de-insider-trading-activity-60e2e3918ead.html

[144] CLOVER HEALTH INVESTMENTS, CORP. /DE SEC Filing

Clover Health Investments, Corp. filed a Form 144 on June 16, 2026, reporting the sale of 14,155 shares of Class A Common Stock. This transaction is related to the vesting of restricted stock units and is a routine resale notice under Rule 144. The filing indicates a neutral impact and sentiment, primarily outlining compliance elements for the sale of these compensation-related shares on Nasdaq.

https://www.stocktitan.net/sec-filings/CLOV/144-clover-health-investments-corp-de-sec-filing-1e8d79914c17.html

Clover Health CEO Jamie Reynoso sells $29,273 in company stock By Investing.com

Clover Health CEO Jamie Reynoso sold 6,350 shares of Class A Common Stock for $29,273, primarily to cover tax withholding obligations from vested restricted stock units. This "sell to cover" transaction was not discretionary. The sale comes as Clover Health's stock is performing well, with a 105% year-to-date return, and the company recently received a Medicare star rating upgrade to 4.5.

https://m.za.investing.com/news/insider-trading-news/clover-health-ceo-jamie-reynoso-sells-29273-in-company-stock-93CH-4330551?ampMode=1

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Clover Health Investments Crop. Price History

19.04.2026 - CLOV Stock was up 5.0%

• The interim CFO of Clover Health, Joseph Clay, had a portion of his RSUs withheld for tax obligations, suggesting positive sentiments about the company's future outlook.
• Fidelity Investments' SEC filing to sell a significant number of shares had a neutral impact on the market, indicating that this action might not be perceived negatively by market participants.
• Despite CEO Brady Patrick Priest selling a substantial amount of shares, analysts continue to forecast profitability for the company this year, potentially bolstering investor confidence.
• The CEO's insider selling of shares, though initially causing some negativity, did not deter investors, potentially highlighting a focus on the company's growth prospects.

15.04.2026 - CLOV Stock was down 5.3%

• The decrease in CLOV's stock price could be linked to the CEO, Brady Patrick Priest, selling a considerable number of shares, potentially indicating uncertainties or lacking confidence within the company.
• Furthermore, the insider selling disclosed in Form 4 filings by both CEO Brady Patrick Priest and CEO Andrew Toy may have triggered concerns among investors, resulting in diminished market trust and a subsequent drop in the stock value.
• Despite analysts forecasting profitability for the ongoing year, the stock's perception of being slightly overvalued, as highlighted in InvestingPro's analysis, might have also played a role in fostering negative sentiment and downward pressure on CLOV's shares.

16.05.2026 - CLOV Stock was up 6.6%

• The bullish movement in CLOV's stock could be attributed to the routine selling of vested shares by the CEO, Jamie Reynoso, which may have positively impacted investor confidence.
• The filing of Form 144 for the sale of vested shares and the CEO's strategic selling under a pre-arranged trading plan could have been perceived as a normal part of executive compensation and not a cause for concern.
• Despite concerns about the stock being overvalued, the CEO's sale of shares at a weighted average price and retaining a significant portion of her holdings could have reassured investors about the company's stability and growth potential.
• Overall, the combination of routine filings, strategic selling by the CEO, and the company's underlying business fundamentals may have contributed to the bullish movement in CLOV's stock today.

18.05.2026 - CLOV Stock was up 5.4%

• Today's rise in Clover Health's stock price reflects positive market sentiment fueled by its strong performance so far in 2021 and the recent upgrade in its Medicare star rating.
• The sale of shares by Clover Health's VP of Finance and Controller to address tax obligations resulting from vested restricted stock units raised initial concerns. However, since these transactions were mandatory rather than optional, they are perceived as part of routine financial management rather than an indication of negative internal sentiments.
• The overall surge in Clover Health's stock value today is likely a result of its robust financial performance, positive industry acknowledgment, and routine financial activities by company executives.
• The market appears to be responding positively to Clover Health's recent achievements and financial decisions, leading to an increase in the stock price amid an optimistic industry outlook.

17.05.2026 - CLOV Stock was down 5.5%

• Today, CLOV faced a decline in the market, which is potentially attributable to insider selling activities:
• CEO Jamie Reynoso and Chief Legal Officer Karen Soares both participated in "sell to cover" transactions to meet tax obligations related to vested restricted stock units.
• Despite being routine and non-discretionary, these insider sales may have influenced a pessimistic investor sentiment, exerting downward pressure on the stock price.
• Although CLOV had positive developments such as the upgraded Medicare star rating and impressive financial performance, the selling activities of key executives might have weighed down on the stock, resulting in today's bearish trend.

03.05.2026 - CLOV Stock was down 5.9%

• Today's downward movement in CLOV stock can be linked to several factors:
• A class action lawsuit alleging false and misleading statements and the withholding of vital information has potentially shaken investor confidence, prompting a sell-off.
• CEO Conrad Wai engaging in significant insider selling of company stock near its 52-week high could have indicated doubt about the company's future prospects.
• Despite the insider sales, Conrad Wai still holds a substantial stake in the company, raising concerns about potential future sales impacting the stock.
• Mixed Q1 2026 earnings were reported, with revenue exceeding forecasts but EPS falling short, potentially fueling negative sentiment around the stock.

02.05.2026 - CLOV Stock was down 5.0%

• The decline in CLOV stock may be linked to the CEO, Conrad Wai, selling a substantial amount of company stock, totaling $879k. This noteworthy insider selling activity could have sparked concerns among investors regarding the company's future prospects.
• The sale of 220,426 shares by the CEO, particularly when the stock was near its 52-week high, might have indicated to investors that insiders perceive the stock as possibly overvalued.
• Furthermore, the mixed Q1 2026 earnings report, where revenue surpassed expectations but EPS fell short, could have also played a role in the negative sentiment surrounding the stock. Investors may have responded unfavorably to the earnings shortfall despite the strong revenue performance.

13.04.2026 - CLOV Stock was up 5.3%

• A tax-related share withholding transaction took place on May 8, 2026, where CEO Andrew Toy withheld 85,704 shares to meet tax obligations. This action might have suggested a positive outlook on the company's future.
• The scheduled quarterly vesting of remaining restricted stock units (RSUs) until August 8, 2026, could have instilled confidence among investors, signaling a strong commitment from the leadership.
• The insider activity, including the aforementioned transactions, likely bolstered shareholder confidence and drew in new investors, influencing CLOV's stock price surge today.

29.04.2026 - CLOV Stock was down 5.6%

• Insider selling: A notable planned sale of shares by a company officer potentially conveyed doubts about the company's future, possibly influencing investor pessimism.
• Rule 10b5-1 trading plan: The implementation of the sale through a pre-arranged trading arrangement might have reinforced negative market perceptions, suggesting a deliberate strategy to divest shares.
• Market reaction: Investors likely viewed the insider selling as a warning sign, prompting a sell-off of CLOV stock and contributing to the day's downward trend.

14.04.2026 - CLOV Stock was up 7.5%

• The bullish movement in CLOV's stock price today may have been influenced by CEO Brady Patrick Priest's sale of shares, which could have boosted investor confidence in the company's future.
• Analysts' positive predictions of profitability for the current year might have contributed to the upward trend in CLOV's stock price, despite concerns about its valuation.
• The recent insider selling of shares by CEO Priest, disclosed in a Form 4 filing, initially raised concerns of insider trading but the market focus appears to have shifted towards the company's positive outlook.
• CEO Andrew Toy's routine share withholding transaction for tax purposes did not seem to have a significant impact on CLOV's market performance today, with investors likely more swayed by profitability forecasts and CEO Priest's share sale.

09.05.2026 - CLOV Stock was up 8.9%

• The bullish movement in CLOV's stock price could be attributed to investors' optimism or positive sentiment surrounding the company despite the ongoing legal challenges.
• The reminders and deadlines for investors to join the class action lawsuits may have already been factored into the stock price, leading to a less significant impact on the market movement.
• Investors may be focusing more on the potential growth prospects and technological innovations of Clover Health rather than the legal issues.
• It's possible that some traders are viewing the current legal challenges as temporary hurdles for the company, leading to increased buying interest and driving the stock price higher.

12.05.2026 - CLOV Stock was down 5.8%

• Today's decline in CLOV's stock price could be linked to the significant sale of CLOV common stock by CEO Jamie Reynoso. This sale may have raised concerns among investors regarding the company's future outlook.
• The disposal of 7,289 shares by Reynoso, although a minor portion of her total holdings, might have indicated skepticism about the current valuation of the stock.
• Furthermore, the analysis suggesting that the stock is presently overpriced could have intensified the selling pressure and contributed to the downward movement.
• Investors could view this insider transaction as a warning sign, fostering pessimism towards CLOV and pushing its stock price downward.